HPV vaccination in people living with HIV: A network meta-analysis highlighting safety, immunogenicity, and evidence gaps.

Authors

Antonio Alves de Souza Neto, Amaxsell Thiago Barros de Souza, Ayane Cristine Alves Sarmento, Ana Katherine Gonçalves, Tolu Adedipe, Kleyton Santos de Medeiros, Janaina Cristiana de Oliveira Crispim

Published in

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. Jun 20, 2026. Epub Jun 20, 2026.

Abstract

HPV infection is a major contributor to cervical and other anogenital cancers, with people living with HIV (PLWH) at particularly high risk due to persistent infection. Although prophylactic HPV vaccines are widely used and generally safe, their efficacy and safety in PLWH remain uncertain.
To evaluate the efficacy and safety of HPV vaccination in PLWH through an overview and network meta-analysis (NMA).
An electronic search was conducted in several databases up to August 12, 2025, without date or language restrictions, using keywords related to HPV vaccines, efficacy, and safety.
We included systematic reviews of randomized controlled trials (RCTs) involving PLWH with HIV who received bivalent (bHPV), quadrivalent (qHPV), or nonavalent (9vHPV) HPV vaccines.
Study selection (Rayyan software) and data extraction were conducted by two independent researchers, and discrepancies were resolved by a third author. Quantitative synthesis was performed using R software. Risk of bias was assessed using AMSTAR 2. The certainty of the evidence was assessed using the Confidence in Network Meta-Analysis (CINeMA).
NMA identified that the qHPV vaccine showed significant immunological efficacy, with a significant increase in seroconversion for anti-HPV 6 (odds ratio [OR]: 17.72; 95% confidence interval [CI]: 2.55, 123.19) and anti-HPV 18 (OR: 22.81; 95% CI: 2.31, 225.32) antibodies, compared to the control group. No significant differences were observed for types 11 and 16. Regarding safety, qHPV demonstrated the best profile regarding pain outcomes at all doses analyzed, with a P score greater than 0.98.
The qHPV vaccine presented the best safety profile regarding pain, including at all doses. Regarding immunological efficacy, significant differences were only found between patients vaccinated with qHPV for anti-HPV 6 and 18. No trials directly evaluated the 9vHPV in PLWH, limiting the applicability of these findings to current vaccination programs.

PMID:
42322124
Bibliographic data and abstract were imported from PubMed on 20 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.